Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA.

Eur Respir J. 2018 Sep 17;52(3). pii: 1801384. doi: 10.1183/13993003.01384-2018. Print 2018 Sep.

PMID:
30139770
2.

Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Wang JM, Robertson SH, Wang Z, He M, Virgincar RS, Schrank GM, Smigla RM, O'Riordan TG, Sundy J, Ebner L, Rackley CR, McAdams P, Driehuys B.

Thorax. 2018 Jan;73(1):21-28. doi: 10.1136/thoraxjnl-2017-210070. Epub 2017 Aug 31.

3.

Quantitative analysis of hyperpolarized 129 Xe gas transfer MRI.

Wang Z, Robertson SH, Wang J, He M, Virgincar RS, Schrank GM, Bier EA, Rajagopal S, Huang YC, O'Riordan TG, Rackley CR, McAdams HP, Driehuys B.

Med Phys. 2017 Jun;44(6):2415-2428. doi: 10.1002/mp.12264. Epub 2017 May 18.

PMID:
28382694
4.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG.

Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7.

PMID:
27939076
5.

Thiazolidinediones are associated with a reduced risk of COPD exacerbations.

Rinne ST, Liu CF, Feemster LC, Collins BF, Bryson CL, O'Riordan TG, Au DH.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 10;10:1591-7. doi: 10.2147/COPD.S82643. eCollection 2015.

6.

Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.

Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O'Riordan TG.

Eur Respir J. 2015 Nov;46(5):1370-7. doi: 10.1183/13993003.01537-2014. Epub 2015 Aug 6.

7.

Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.

O'Riordan TG, Smith V, Raghu G.

Chest. 2015 Oct;148(4):1083-1092. doi: 10.1378/chest.14-3218. Review.

PMID:
26020856
8.

Rational Drug Development for Mucous Dehydration and Mucous Metaplasia.

O'Riordan TG.

J Aerosol Med Pulm Drug Deliv. 2015 May 14. [Epub ahead of print]

PMID:
25974653
9.

Duration of action of hypertonic saline on mucociliary clearance in the normal lung.

Bennett WD, Wu J, Fuller F, Balcazar JR, Zeman KL, Duckworth H, Donn KH, O'Riordan TG, Boucher RC, Donaldson SH.

J Appl Physiol (1985). 2015 Jun 15;118(12):1483-90. doi: 10.1152/japplphysiol.00404.2014. Epub 2015 Apr 24.

10.

Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores.

Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF.

Thorax. 2015 Jan;70(1):12-20. doi: 10.1136/thoraxjnl-2014-205918. Epub 2014 Oct 16.

PMID:
25323621
11.

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.

Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG.

Lancet Respir Med. 2014 Sep;2(9):738-49. doi: 10.1016/S2213-2600(14)70165-1. Epub 2014 Aug 18.

PMID:
25154045
12.

Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study.

Rinne ST, Feemster LC, Collins BF, Au DH, Perkins M, Bryson CL, O'Riordan TG, Liu CF.

Allergy Asthma Clin Immunol. 2014 Jul 3;10(1):34. doi: 10.1186/1710-1492-10-34. eCollection 2014.

13.

Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT--authors' reply.

Raghu G, O'Riordan TG.

Lancet Respir Med. 2014 May;2(5):e5-6. doi: 10.1016/S2213-2600(14)70098-0. No abstract available.

PMID:
24815807
14.

Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial.

Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, Behr J, Brown KK, Egan JJ, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Pedersen PS, Sood R, Montgomery AB, O'Riordan TG.

Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6. Epub 2014 Feb 18.

PMID:
24717624
15.

A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.

Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF.

Chest. 2014 Aug;146(2):437-448. doi: 10.1378/chest.13-1891. Review. Erratum in: Chest. 2014 Nov;146(5):1422.

PMID:
24626872
16.

Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.

Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE Jr, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP.

Am J Respir Crit Care Med. 2014 Jan 15;189(2):214-22. doi: 10.1164/rccm.201306-1141WS.

17.

Airway drug pharmacokinetics via analysis of exhaled breath condensate.

Esther CR Jr, Boucher RC, Johnson MR, Ansede JH, Donn KH, O'Riordan TG, Ghio AJ, Hirsh AJ.

Pulm Pharmacol Ther. 2014 Feb;27(1):76-82. doi: 10.1016/j.pupt.2013.07.009. Epub 2013 Aug 7.

18.

Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411.

O'Riordan TG, Donn KH, Hodsman P, Ansede JH, Newcomb T, Lewis SA, Flitter WD, White VS, Johnson MR, Montgomery AB, Warnock DG, Boucher RC.

J Aerosol Med Pulm Drug Deliv. 2014 Jun;27(3):200-8. doi: 10.1089/jamp.2013.1037. Epub 2013 Aug 1.

PMID:
23905576
19.

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators*.

Ann Intern Med. 2013 May 7;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003. Erratum in: Ann Intern Med. 2014 May 6;160(9):658.

PMID:
23648946
20.

Differences in prevalence of geohelminth infections between indigenous and settler populations in a remote Amazonian region of Peru.

Briones-Chávez C, Torres-Zevallos H, Canales M, Stamato CM, O'Riordan TG, Terashima A.

Trop Med Int Health. 2013 May;18(5):615-8. doi: 10.1111/tmi.12077. Epub 2013 Feb 14.

21.

Aerosolized iloprost customized for the critically ill.

Harris KW, O'Riordan TG, Smaldone GC.

Respir Care. 2007 Nov;52(11):1507-9.

22.
23.

Antiprotease function of airway secretions in purulent tracheobronchitis.

O'Riordan TG, Seischab LB, Ying QL, Colon-Carreras E, Chughtari B, Palmer LB, Simon SR.

Chest. 2005 Nov;128(5):3167-76.

PMID:
16304258
24.

Aerosol delivery devices and obstructive airway disease.

O'Riordan TG.

Expert Rev Med Devices. 2005 Mar;2(2):197-203. Review.

PMID:
16293056
25.

Potential role of inhibitors of neutrophil elastase in treating diseases of the airway.

Chughtai B, O'Riordan TG.

J Aerosol Med. 2004 Winter;17(4):289-98. Review.

PMID:
15684729
26.

Respiratory medical societies and the threat of bioterrorism.

O'Riordan TG, Smaldone GC.

Thorax. 2004 Mar;59(3):265-7. Review.

27.
28.
29.

Formulations and nebulizer performance.

O'Riordan TG.

Respir Care. 2002 Nov;47(11):1305-12; discussion 1312-3. Review.

PMID:
12425745
30.

Optimizing delivery of inhaled corticosteroids: matching drugs with devices.

O'Riordan TG.

J Aerosol Med. 2002 Fall;15(3):245-50. Review.

PMID:
12396412
31.

Effects of unilateral bronchoconstriction on distribution of aerosols in ovine airways.

Sabater JR, Atkins ND, Wanner A, O'Riordan TG.

J Aerosol Med. 2001 Fall;14(3):369-75.

PMID:
11693849
32.

Inhaled antimicrobial therapy: from cystic fibrosis to the flu.

O'Riordan TG.

Respir Care. 2000 Jul;45(7):836-45. Review.

PMID:
10926381
33.

Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep.

Sabater JR, Mao YM, Shaffer C, James MK, O'Riordan TG, Abraham WM.

J Appl Physiol (1985). 1999 Dec;87(6):2191-6.

34.

A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine.

Kemp JP, DeGraff AC Jr, Pearlman DS, Wang Y, Arledge TE, Welch MB, O'Riordan TG, Herrle MR, Stahl EG.

J Allergy Clin Immunol. 1999 Dec;104(6):1189-97.

PMID:
10589000
35.

Bench testing of nebulizers: a comparison of three methods.

O'Riordan TG, Weinstein MD, Mao Y.

J Aerosol Med. 1999 Summer;12(2):59-66.

PMID:
10539708
36.

Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma.

Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, O'Riordan TG, Bevilacqua MP, Abraham WM.

J Pharmacol Exp Ther. 1999 May;289(2):1007-14.

PMID:
10215681
37.

Budesonide affects allergic mucociliary dysfunction.

O'Riordan TG, Mao Y, Otero R, Lopez J, Sabater JR, Abraham WM.

J Appl Physiol (1985). 1998 Sep;85(3):1086-91.

38.

Aerosolized antibiotics in mechanically ventilated patients: delivery and response.

Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A.

Crit Care Med. 1998 Jan;26(1):31-9.

PMID:
9428540
39.

Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways.

O'Riordan TG, Otero R, Mao Y, Lauredo I, Abraham WM.

Am J Respir Crit Care Med. 1997 May;155(5):1522-8.

PMID:
9154852
40.

Effect of nebulizer configuration on delivery of aerosolized tobramycin.

O'Riordan TG, Amram JC.

J Aerosol Med. 1997 Spring;10(1):13-23.

PMID:
10166359
41.

Mucociliary clearance in the airways.

Wanner A, Salathé M, O'Riordan TG.

Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1868-902. Review. No abstract available.

PMID:
8970383
42.

Treatment of mucociliary dysfunction.

Salathe M, O'Riordan TG, Wanner A.

Chest. 1996 Oct;110(4):1048-57. Review. No abstract available.

PMID:
8874267
43.

Endothelin-1 depresses tracheal mucus velocity in ovine airways via ET-A receptors.

Sabater JR, Otero R, Abraham WM, Wanner A, O'Riordan TG.

Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):341-5.

PMID:
8756804
44.

Aerosolized cyclosporine in lung recipients with refractory chronic rejection.

Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori NP, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O'Riordan TG, Zendarsky MM, Yousem SA, Griffith BP.

Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1451-5.

PMID:
8616581
45.

Delivery and distribution of aerosolized cyclosporine in lung allograft recipients.

O'Riordan TG, Iacono A, Keenan RJ, Duncan SR, Burckart GJ, Griffith BP, Smaldone GC.

Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):516-21.

PMID:
7842214
46.

Regional deposition and regional ventilation during inhalation of pentamidine.

O'Riordan TG, Smaldone GC.

Chest. 1994 Feb;105(2):396-401.

PMID:
8306735
47.

Lobar pentamidine levels and Pneumocystis carinii pneumonia following aerosolized pentamidine.

O'Riordan TG, Baughman RP, Dohn MN, Smaldone GC.

Chest. 1994 Jan;105(1):53-6.

PMID:
8275783
48.

Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery.

O'Riordan TG, Palmer LB, Smaldone GC.

Am J Respir Crit Care Med. 1994 Jan;149(1):214-9.

PMID:
8111585
49.

Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease.

Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback EG.

Chest. 1993 May;103(5):1390-6.

PMID:
8486016
50.

Changing patterns of aerosol deposition during methacholine bronchoprovocation.

O'Riordan TG, Walser L, Smaldone GC.

Chest. 1993 May;103(5):1385-9.

PMID:
8486015

Supplemental Content

Loading ...
Support Center